Drug intelligence / Profile preview

QL-1706 + albumin-bound paclitaxel + cisplatin + S1

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

QL-1706 + modified TPF regimen is a combination therapy being investigated for the treatment of locally advanced nasopharyngeal carcinoma. QL-1706 (also known as iparomlimab/tuvonralimab or PSB205) is a first-in-class bifunctional antibody mixture developed using proprietary MabPair technology, which allows for the simultaneous production of two distinct monoclonal antibodies—iparomlimab (an anti-PD-1 IgG4 antibody) and tuvonralimab (an anti-CTLA-4 IgG1 antibody)—from a single cell line. The modified TPF regimen in this specific clinical context consists of albumin-bound paclitaxel (a microtubule stabilizer), cisplatin (a DNA-crosslinking agent), and S1 (an oral fluoropyrimidine consisting of tegafur, gimeracil, and oteracil). This combination aims to leverage the synergistic effects of dual immune checkpoint blockade and cytotoxic chemotherapy to improve outcomes in patients with nasopharyngeal carcinoma. The regimen is currently being evaluated in a Phase 2 clinical trial led by The First Affiliated Hospital of Xiamen University.

Other names: Iparomlimab/Tuvonralimab + modified TPF regimenQL-1706 + nab-paclitaxel + cisplatin + S1QL-1706 + modified TPF regimen

Targets

PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNACTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))OPRT (Orotidine 5'-phosphate decarboxylase)DPYD (Dihydropyrimidine dehydrogenase)

Beyond the preview

Go deeper on QL-1706 + albumin-bound paclitaxel + cisplatin + S1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-1706 + albumin-bound paclitaxel + cisplatin + S1.

Explore the full profile